Ceftibuten: Difference between revisions

Jump to navigation Jump to search
No edit summary
No edit summary
Line 20: Line 20:
'''| [[Ceftibuten overdosage|Overdosage]]'''
'''| [[Ceftibuten overdosage|Overdosage]]'''
'''| [[Ceftibuten dosage and administration|Dosage and Administration]]'''
'''| [[Ceftibuten dosage and administration|Dosage and Administration]]'''
'''| [[Ceftibuten cclinical studies|Clinical Studies]]'''
'''| [[Ceftibuten clinical studies|Clinical Studies]]'''
'''| [[Ceftibuten how supplied|How Supplied]]'''
'''| [[Ceftibuten how supplied|How Supplied]]'''
'''| [[Ceftibuten labels and packages|Labels and Packages]]'''
'''| [[Ceftibuten labels and packages|Labels and Packages]]'''

Revision as of 03:38, 31 December 2013

Ceftibuten
CEDAX® FDA Package Insert
Description
Clinical Pharmacology
Microbiology
Indications and Usage
Contraindications
Warnings and Precautions
Adverse Reactions
Overdosage
Dosage and Administration
Clinical Studies
How Supplied
Labels and Packages

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1];Associate Editor(s)-in-Chief: Abdurahman Khalil, M.D. [2]

Overview

Ceftibuten is a third-generation cephalosporin antibiotic. It is an orally-administered agent, with 2 dosage forms, capsule or oral suspension. It is marketed by Shionogi USA under the trade name Cedax®

Category

Cephalosporins,third generation.

US Brand Names

CEDAX®

FDA Package Insert

Description | Clinical Pharmacology | Microbiology | Indications and Usage | Contraindications | Warnings and Precautions | Adverse Reactions | Overdosage | Dosage and Administration | Clinical Studies | How Supplied | Labels and Packages

References

http://www.accessdata.fda.gov/drugsatfda_docs/label/2011/050686s016lbl.pdf